Patents by Inventor Hans Iding

Hans Iding has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180134685
    Abstract: The present invention provides a process for the manufacture of a compound of formula VIIIa and salts forms of VIIIa where Rc is an aryl sulfonic acid
    Type: Application
    Filed: January 10, 2018
    Publication date: May 17, 2018
    Applicant: Genentech, Inc.
    Inventors: Jinguang Lin, Alexandra Chestakova, Wei Gu, Hans Iding, Jing Li, Xin Linghu, Patrik Meier, Chunbo Sha, Jeffrey Stults, Youchu Wang, Haiming Zhang, Jianqian Zhang, Tao Zhang
  • Publication number: 20180086722
    Abstract: The present invention relates to a process for the preparation of a compound of formula (I) wherein R1 is as defined herein, which is useful as an intermediate in the preparation of active pharmaceutical compounds.
    Type: Application
    Filed: November 30, 2017
    Publication date: March 29, 2018
    Applicant: GENENTECH, INC.
    Inventors: Hans Iding, Reinhard Reents, Michelangelo Scalone, Francis Gosselin
  • Patent number: 9862689
    Abstract: The present invention relates to a process for the preparation of a compound of formula (I), wherein R1 is as defined herein, which is useful as an intermediate in the preparation of active pharmaceutical compounds.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: January 9, 2018
    Assignee: GENENTECH, INC.
    Inventors: Hans Iding, Reinhard Reents, Michelangelo Scalone, Francis Gosselin
  • Publication number: 20170247338
    Abstract: The present disclosure relates to processes for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds, and more particularly relates to processes for preparing (R)-4-(5-methyl-7-oxo-6,7-dihydro-5H-cyclopenta[d] pyrimidin-4-yl)piperazine and N-protected derivatives thereof, which may be used as an intermediate in the synthesis of Ipatasertib (i.e., (S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)-propan-1-one). The present disclosure additionally relates to various compounds that are intermediates employed in these processes.
    Type: Application
    Filed: September 25, 2015
    Publication date: August 31, 2017
    Inventors: Francis Gosselin, Chong Han, Hans Iding, Reinhard Reents, Scott Savage, Beat Wirz
  • Publication number: 20170022183
    Abstract: The present invention provides a process for the manufacture of a compound of formula VIIIa and salts forms of VIIIa where Rc is an aryl sulfonic acid
    Type: Application
    Filed: October 5, 2016
    Publication date: January 26, 2017
    Applicant: Genentech, Inc.
    Inventors: Jinguang Lin, Alexandra Chestakova, Wei Gu, Hans Iding, Jing Li, Xin Linghu, Patrik Meier, Chunbo Sha, Jeffrey Stults, Youchu Wang, Haiming Zhang, Jianqian Zhang, Tao Zhang
  • Patent number: 9527810
    Abstract: The present invention is concerned with a novel process for the preparation of a compound of formula I and its hydrates The compounds of formula I and the corresponding hydrates are pharmaceutically active substances.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: December 27, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jean-Michel Adam, Charles Alois Dvorak, Daniel Fishlock, Eric R. Humphreys, Hans Iding, Christophe Pfleger, Pankaj D. Rege, Xianqing Shi, Justin Vitale, Shaoning Wang, Marian Zajac
  • Publication number: 20160304843
    Abstract: The present invention relates to a mutant transaminase with increased transaminase activity relative to the wild-type transaminase, a fusion protein comprising the transaminase, a polynucleotide coding for the transaminase, a host cell comprising the polynucleotide, mutant transaminase and/or fusion protein, a method of producing an amine with the mutant transaminase or fusion protein and the use of the mutant transaminase or fusion protein for the production of an amine.
    Type: Application
    Filed: April 15, 2016
    Publication date: October 20, 2016
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Steven Paul HANLON, Hans IDING, Paul SPURR, Beat WIRZ, Uwe BORNSCHEUER, Ioannis PAVLIDIS, Martin Steffen WEISS
  • Publication number: 20160297773
    Abstract: The present invention relates to a process for the preparation of a compound of formula (I), wherein R1 is as defined herein, which is useful as an intermediate in the preparation of active pharmaceutical compounds.
    Type: Application
    Filed: November 13, 2014
    Publication date: October 13, 2016
    Applicant: GENENTECH, INC.
    Inventors: Hans IDING, Reinhard REENTS, Michelangelo SCALONE, Francis GOSSELIN
  • Publication number: 20160289718
    Abstract: The invention relates to a novel process for the preparation of chiral 2-(4-aminophenyl) morpholines of the formula wherein R1 is hydrogen an amino protecting group. The chiral 2-(4-aminophenyl) morpholines of the formula I are key intermediates for the preparation of compounds that have a good affinity to the trace amine associated receptors (TAARs).
    Type: Application
    Filed: June 7, 2016
    Publication date: October 6, 2016
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Rene Trussardi, Hans Iding
  • Publication number: 20150045408
    Abstract: The present invention is concerned with a novel process for the preparation of a compound of formula I and its hydrates The compounds of formula I and the corresponding hydrates are pharmaceutically active substances.
    Type: Application
    Filed: October 24, 2014
    Publication date: February 12, 2015
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Jean-Michel Adam, Charles Alois Dvorak, Daniel Fishlock, Eric R. Humphreys, Hans Iding, Christophe Pfleger, Pankaj D. Rege, Xianqing Shi, Justin Vitale, Shaoning Wang, Marian Zajac
  • Patent number: 8604062
    Abstract: The present invention relates to a process for the preparation of a compound of formula (I) wherein R1 and R2 are as defined herein, which is useful as an intermediate in the preparation of active pharmaceutical compounds.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: December 10, 2013
    Assignee: Hoffman-La Roche Inc.
    Inventors: Pascal Dott, Steven Paul Hanlon, Stefan Hildbrand, Hans Iding, Andrew Thomas, Pius Waldmeier
  • Publication number: 20110054174
    Abstract: The present invention relates to a process for the preparation of a compound of formula I, wherein R1 is C1-6-alkyl and R2 is hydrogen or halogen. (R)-2-phenyl propionic acid derivatives of formula I are key intermediates in the synthesis of 5-substituted-pyrazine or pyridine glucokinase activators of the formula Xa, which have the potential to be useful for the treatment and/or prophylaxis of type II diabetes.
    Type: Application
    Filed: August 20, 2010
    Publication date: March 3, 2011
    Inventors: Stephan Bachmann, Alec Fettes, Hans Iding, Beat Wirz, Ulrich Zutter
  • Patent number: 7872141
    Abstract: The invention is concerned with processes for the manufacture of the pyrrolidine-3,4-dicarboxamide derivative of formula (I), and the intermediates useful for those processes of manufacture.
    Type: Grant
    Filed: December 19, 2007
    Date of Patent: January 18, 2011
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Jean-Michel Adam, Pascal Dott, Hans Iding, Hans-Juergen Mair, Reinhard Reents, Beat Wirz
  • Patent number: 7838693
    Abstract: The present invention provides novel methods for preparing a key intermediate, 3,5-di-O-acyl-2-fluoro-2-C-methyl-D-ribono-?-lactone (2), for the preparation of 1-(2-deoxy-2-fluoro-2-C-methyl-?-D-ribofuranosyl)cytosine (1), which is a potent and selective anti-hepatitis C virus agent.
    Type: Grant
    Filed: December 11, 2007
    Date of Patent: November 23, 2010
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Miall Cedilote, Thomas Cleary, Hans Iding, Pingsheng Zhang
  • Patent number: 7727750
    Abstract: The present invention relates to biocatalytic asymmetric reduction for the preparation of 2-amino-[5-(1-hydroxy-2-hydroxy or halogen-ethyl)]-pyrazine derivatives of the formula wherein R is lower alkylcarbonyl or an amino protecting group and R1 is hydroxy or halogen. The compounds are key intermediates in the manufacture of a glucokinase activator.
    Type: Grant
    Filed: April 3, 2008
    Date of Patent: June 1, 2010
    Assignee: Hoffman-La Roche Inc.
    Inventors: Steven Paul Hanlon, Hans Iding, Ernst Kupfer, Roumen Nikolaev Radinov, Lianhe Shu, Ping Wang
  • Patent number: 7642366
    Abstract: The invention is concerned with new phosphine ligands of the formula I wherein R1 and R2 are independently of each other alkyl, aryl, cycloalkyl or heteroaryl, said alkyl, aryl, cycloalkyl or heteroaryl may be substituted by alkyl, alkoxy, halogen, hydroxy, amino, mono- or dialkylamino, aryl, —SO2—R7, —SO3?, —CO—NR8R8?, carboxy, alkoxycarbonyl, trialkylsilyl, diarylalkylsilyl, dialkylarylsilyl or triarylsilyl; R3 is alkyl, cycloalkyl, aryl or heteroaryl; R4? and R4 signify independently of each other hydrogen, alkyl or optionally substituted aryl; or R4? and R4 together with the C-atom they are attached to form a 3-8-membered carbocyclic ring; dotted line is absent or is present and forms a double bond; R5 and R6 are independently of each other hydrogen, alkyl or aryl; or linked together to form a 3-8-membered carbocyclic ring or an aromatic ring; R7 is alkyl, aryl or NR8R8?; and R8 and R8? are independently of each other hydrogen, alkyl or aryl; metal complexes with such ligands as well as the use of su
    Type: Grant
    Filed: November 1, 2006
    Date of Patent: January 5, 2010
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Hans Iding, Ernst Kupfer, Bruno Lohri, Kazimierz Michal Pietrusiewicz, Kurt Puentener, Michelangelo Scalone, Wioleta Swierczynska, Beat Wirz
  • Publication number: 20090326253
    Abstract: The invention is concerned with new phosphine ligands of the formula I wherein R1 and R2 are independently of each other alkyl, aryl, cycloalkyl or heteroaryl, said alkyl, aryl, cycloalkyl or heteroaryl may be substituted by alkyl, alkoxy, halogen, hydroxy, amino, mono- or dialkylamino, aryl, —SO2—R7, —SO3?, —CO—NR8R8?, carboxy, alkoxycarbonyl, trialkylsilyl, diarylalkylsilyl, dialkylarylsilyl or triarylsilyl; R3 is alkyl, cycloalkyl, aryl or heteroaryl; R4? and R4 signify independently of each other hydrogen, alkyl or optionally substituted aryl; or R4? and R4 together with the C-atom they are attached to form a 3-8-membered carbocyclic ring; dotted line is absent or is present and forms a double bond; R5 and R6 are independently of each other hydrogen, alkyl or aryl; or linked together to form a 3-8-membered carbocyclic ring or an aromatic ring; R7 is alkyl, aryl or NR8R8?; and R8 and R8? are independently of each other hydrogen, alkyl or aryl; metal complexes with such ligands as well as the use of suc
    Type: Application
    Filed: September 11, 2009
    Publication date: December 31, 2009
    Inventors: Hans Iding, Ernst Kupfer, Bruno Lohri, Kazimierz Michal Pietrusiewicz, Kurt Puentener, Michelangelo Scalone, Wioleta Swierczynska, Beat Wirz
  • Patent number: 7629346
    Abstract: The present invention relates to compounds of the formula I: wherein R1 to R8 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors, such as obesity.
    Type: Grant
    Filed: May 30, 2007
    Date of Patent: December 8, 2009
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Paul Hebeisen, Hans Iding, Matthias Heinrich Nettekoven, Ulrike Obst Sander, Stephan Roever, Urs Weiss, Beat Wirz
  • Publication number: 20090270360
    Abstract: The invention is concerned with novel dicarboxamide derivatives of formula (I) wherein A, B, Rc, D and E are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.
    Type: Application
    Filed: January 16, 2009
    Publication date: October 29, 2009
    Inventors: Markus Boehringer, Katrin Groebke Zbinden, Wolfgang Haap, Hans Hilpert, Jacques Himber, Roland Humm, Hans Iding, Dietmar Knopp, Narendra Panday, Fabienne Ricklin, Christoph Martin Stahl
  • Patent number: 7501413
    Abstract: The invention is concerned with novel dicarboxamide derivatives of formula (I) wherein A, B, Rc, D and E are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.
    Type: Grant
    Filed: October 31, 2005
    Date of Patent: March 10, 2009
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Markus Boehringer, Katrin Groebke Zbinden, Wolfgang Haap, Hans Hilpert, Jacques Himber, Roland Humm, Hans Iding, Dietmar Knopp, Narendra Panday, Fabienne Ricklin, Christoph Martin Stahl